Eur Urol Oncol 2022 Jul 7
Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Related Questions
Per the NCCN guidelines and clinical trials, the patient does not fit the criteria for low metastatic burden, and therefore the benefit of radiation t...
New answer by Radiation Oncologist at UC San Diego (May 12, 2024)
Given the clarifications provided (lung met is biopsy-proven prostate cancer and visible on CT), systemic therapy is clearly the priority. Drs. @Patel and @Felefly have provid...